Work

A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6502

Authors: Hannah Goulart, Marina Konopleva, Nitin Jain, Naval Guastad Daver, Courtney Denton DiNardo, Tapan M. Kadia, Farhad Ravandi-Kashani, Yesid Alvarado, Fadi Haddad, Koichi Takahashi, Gautam Borthakur, Sherry Pierce, Susan Wahl, Allison Pike, Elias Jabbour, Sanam Loghavi, Muzaffar H. Qazilbash, Guillermo Garcia-Manero, Naveen Pemmaraju

Institutions: The University of Texas MD Anderson Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162502525

Cites:

Cited by: 1

Related to: